<p>Preparations of MB-435- α6HG6 cells were continuously infused with either of two anti-integrin mAbs. A. Untreated control preparation of aggregates (blue) undergoing coalescence between 338 and 426 hours. In this period, eight of the nine aggregates coalesced. B. A preparation of aggregates (blue) treated with the anti-ß-1 integrin mAb, AIIB2, underwent growth but did not coalesce. C. A preparation of aggregates (blue) treated with the anti-α-3 integrin mAB, P1B5, underwent accelerated coalescence, and exhibited a massive increase in the formation of probe cells (red), many of which exited the aggregates.</p
The study of aggregation propensity of a monoclonal antibody (mAb) and its sensitivity to applied st...
Purpose To detect and characterize the aggregation of therapeutic monoclonal antibodies in undiluted...
The immunogenic potential of therapeutic proteins has been known for over half a century. However, t...
Protein aggregation is a major concern during monoclonal antibody (mAb) production [1,2]. The presen...
Protein aggregates represent a safety, immunological and stability concern in therapeutic protein fo...
An IgG2 monoclonal antibody (mAb) solution was subjected to stirring, generating high concentrations...
One of the dominant classes of protein based drugs, which continues to contribute to the growth and ...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
A paradox in monoclonal antibody (mAb) therapy is that despite the well-documented tolerogenic prope...
Therapeutic proteins have become invaluable in treating a wide range of serious and life-threatening...
In the manufacturing process of therapeutic monoclonal antibodies (mAbs) aggregate formation is a cr...
Aggregates in protein therapeutics like IgG monoclonal antibodies (mAb) are detrimental to product s...
Monoclonal antibody (MAb) production using immobilized hybridoma cells and free cells were compared ...
The study of aggregation propensity of a monoclonal antibody (mAb) and its sensitivity to applied st...
Purpose To detect and characterize the aggregation of therapeutic monoclonal antibodies in undiluted...
The immunogenic potential of therapeutic proteins has been known for over half a century. However, t...
Protein aggregation is a major concern during monoclonal antibody (mAb) production [1,2]. The presen...
Protein aggregates represent a safety, immunological and stability concern in therapeutic protein fo...
An IgG2 monoclonal antibody (mAb) solution was subjected to stirring, generating high concentrations...
One of the dominant classes of protein based drugs, which continues to contribute to the growth and ...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
Therapeutic antibodies have the potential to induce immunogenicity leading to the development of ant...
A paradox in monoclonal antibody (mAb) therapy is that despite the well-documented tolerogenic prope...
Therapeutic proteins have become invaluable in treating a wide range of serious and life-threatening...
In the manufacturing process of therapeutic monoclonal antibodies (mAbs) aggregate formation is a cr...
Aggregates in protein therapeutics like IgG monoclonal antibodies (mAb) are detrimental to product s...
Monoclonal antibody (MAb) production using immobilized hybridoma cells and free cells were compared ...
The study of aggregation propensity of a monoclonal antibody (mAb) and its sensitivity to applied st...
Purpose To detect and characterize the aggregation of therapeutic monoclonal antibodies in undiluted...
The immunogenic potential of therapeutic proteins has been known for over half a century. However, t...